Inhalation product licensing opportunities

Skyepharma has a number of inhalation licensing opportunities.

flutiform® is a fixed-dose combination of the commonly prescribed corticosteroid fluticasone propionate and the fast-onset long-acting β2 adrenergic agonist formoterol fumarate dihydrate in a pressurised Metered Dose Inhaler (pMDI). It has been partnered with major pharmaceutical companies for a number of markets, and has already been launched in several European countries and in Japan. It is available for partnering in other countries as listed below.

Territory

Status

Additional comments

United States

Available
for licensing
 

Significant development work has been undertaken in connection with NDA

Canada

Available
for licensing

India, Sri Lanka, Nepal, Bangladesh, Bhutan

Available
for licensing


 

Skyepharma's enabling and problem-solving formulation technologies and SkyeHaler™ multi-dose DPI device platform are also available for licensing.

Contact us if you are interested in discussing collaboration.

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens
London
SW1W 0EB
UK

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz
Switzerland

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.